Your browser doesn't support javascript.
loading
A phase 1 study to evaluate the safety, tolerability and pharmacokinetics of TAK-041 in healthy participants and patients with stable schizophrenia.
Yin, Wei; Han, David; Khudyakov, Polyna; Behrje, Rhett; Posener, Joel; Laurenza, Antonio; Arkilo, Dimitrios.
  • Yin W; Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.
  • Han D; Parexel, Glendale, CA, USA.
  • Khudyakov P; Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.
  • Behrje R; Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.
  • Posener J; Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.
  • Laurenza A; Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.
  • Arkilo D; Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.
Br J Clin Pharmacol ; 88(8): 3872-3882, 2022 08.
Article en En | MEDLINE | ID: mdl-35277995
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Esquizofrenia Límite: Adult / Humans Idioma: En Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Esquizofrenia Límite: Adult / Humans Idioma: En Año: 2022 Tipo del documento: Article